Van Horn R. Lawrence
Van Horn R. Lawrence's purchase track record
How the stock did after each of Van Horn R. Lawrence's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/28/2025 | CHCT | $193K | -3.4% | +3.2% | +15.7% |
| 9/9/2024 | CHCT | $161K | +18.8% | +22.6% | +2.6% |
| 8/5/2024 | CHCT | $49K | -0.9% | +7.4% | +15.6% |
| 3/10/2023 | CHCT | $25K | -0.2% | -5.4% | +15.4% |
| 12/22/2022 | HROW | $25K | +27.9% | +37.3% | +14.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Harrow (HROW) gains analyst support and conference buzz amid turnaround focus. Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.
Transaction History
| CHCT | ▲ Buy | Grant | 7,661 | $132K | 5/21/2026 | View on chart |
| CHCT | ▲ Buy | Grant | 6,222 | $0 | 5/7/2026 | View on chart |
| CHCT | ▲ Buy | Open Market | 11,815 | $193K | 5/28/2025 | View on chart |
| CHCT | ▲ Buy | Grant | 7,933 | $132K | 5/15/2025 | View on chart |
| CHCT | ▲ Buy | Grant | 6,524 | $0 | 5/1/2025 | View on chart |
| CHCT | ▲ Buy | Open Market | 10,000 | $161K | 9/9/2024 | View on chart |
| CHCT | ▲ Buy | Open Market | 2,500 | $49K | 8/5/2024 | View on chart |
| CHCT | ▲ Buy | Grant | 5,439 | $132K | 5/16/2024 | View on chart |
| CHCT | ▲ Buy | Grant | 4,414 | $0 | 5/2/2024 | View on chart |
| CHCT | ▲ Buy | Grant | 2,933 | $104K | 5/19/2023 | View on chart |
| CHCT | ▲ Buy | Grant | 2,751 | $0 | 5/4/2023 | View on chart |
| CHCT | ▲ Buy | Open Market | 685 | $25K | 3/10/2023 | View on chart |
| HROW | ▲ Buy | Open Market | 1,860 | $25K | 12/22/2022 | View on chart |
| CHCT | ▲ Buy | Grant | 2,840 | $104K | 5/20/2022 | View on chart |
| CHCT | ▲ Buy | Grant | 2,693 | $0 | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Evercore ISI Lowers CHCT Price Target to $17
Evercore ISI Group has maintained its In-Line rating on Community Healthcare Trust but lowered its price target to $17. This move places the firm's estimate at the lower end of the current analyst range, which spans from $17.00 to $18.00. The adjustment reflects a modestly more conservative outlook for the company's near-term performance relative to previous expectations.
Evercore ISI Lowers CHCT Price Target to $17. Evercore ISI Group has maintained its In-Line rating on Community Healthcare Trust but lowered its price target to $17. This move places the firm's estimate at the lower end of the current analyst range, which spans from $17.00 to $18.00. The adjustment reflects a modestly more conservative outlook for the company's near-term performance relative to previous expectations.